Caldera Therapeutics
Caldera Therapeutics Launches with $112.5M Funding for China-Licensed IBD Bispecific Antibody
Caldera Therapeutics; IBD; bispecific antibody; $112.5M funding; Qyuns Therapeutics; CLD-423
Actionable Insights Powered by AI
Caldera Therapeutics; IBD; bispecific antibody; $112.5M funding; Qyuns Therapeutics; CLD-423